Mark A. Morgan, MD, FACOG, FACS, Chief, Gynecologic Oncology at Fox Chase Cancer Center
I’m stepping in this week to congratulate the author of this blog – my colleague, Robert Burger, MD, FACOG, FACS. He received the prestigious Rosalind Franklin Excellence in Ovarian Cancer Research Award on Monday, July 11, 2011, at the Ovarian Cancer National Alliance’s 14th annual conference in Washington, D.C.
As the director of Fox Chase’s Women’s Cancer Center, Dr. Burger is currently involved in groundbreaking research, including a study of molecular targeted therapeutics and novel primary prevention strategies. He is also the principal investigator for Phase II and Phase III trials of anti-angiogenic therapy for patients with ovarian cancer.
At Fox Chase, Dr. Burger also serves as Associate Director for Research, Section of Gynecologic Oncology; Professor, Department of Surgical Oncology; and Attending Surgeon, Gynecologic Oncology.
During his acceptance speech, Dr. Burger stressed the need to “extend progression-free survival and improve quality of life for patients.”
Michael Seiden, MD, PhD, President and CEO of Fox Chase, delivered an overview of ovarian cancer at the conference’s opening plenary session on Sunday, July 10.
The Rosalind Franklin Excellence in Ovarian Cancer Research Award honors the memory of Dr. Rosalind Elsie Franklin, the renowned British molecular biologist who succumbed to ovarian cancer at age 37 in 1958. She is credited with a pioneering role in the research and discovery of the structure of DNA.
Recipients of the award honor Franklin’s legacy with their devotion to medical research. Past winners are George Coukos, MD, PhD (Abramson Cancer Center, UPenn); Nicole Urban, ScD (Fred Hutchinson Cancer Research Center); Robert Bast, MD (MD Anderson Cancer Center); Deborah Armstrong, MD (Kimmel Cancer Center, Johns Hopkins); Elise Kohn, MD (Center for Cancer Research); and Barbara Goff, MD (Seattle Cancer Care Alliance).
Please join me in congratulating Dr. Burger on this truly outstanding accomplishment.
Mark A. Morgan, MD, FACOG, FACS